George L. Fotiades
Known title: DirectorCIK: 0001202424
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
AptarGroup Secures CE Marking for LuerVax as UBS Starts Coverage. AptarGroup announced that its LuerVax product and accompanying spray divider have received CE marking, a regulatory step that supports vaccine developers. Separately, UBS initiated coverage on the stock with a neutral rating and a price target of $135. The company's average analyst target remains $162.00, with a range extending to $220.00.
Transaction History
| PLD | ▲ Buy | Option Exercise | 1,687 | $0 | 9/17/2026 | View on chart |
| ATR | ▲ Buy | Grant | 151 | $0 | 7/16/2026 | View on chart |
| ATR | ▲ Buy | Grant | 1,326 | $0 | 5/6/2026 | View on chart |
| PLD | ▼ Sell | Gift | 1,824 | $0 | 12/9/2025 | View on chart |
| PLD | ▲ Buy | Option Exercise | 1,824 | $0 | 6/1/2025 | View on chart |
| ATR | ▲ Buy | Grant | 1,069 | $0 | 5/7/2025 | View on chart |
| ATR | ▼ Sell | Gift | 2,175 | $0 | 11/1/2024 | View on chart |
| ATR | ▲ Buy | Grant | 1,113 | $0 | 5/1/2024 | View on chart |
| ATR | ▲ Buy | Option Exercise | 9,500 | $633K | 8/28/2023 | View on chart |
| ATR | ▼ Sell | Open Market | 9,200 | $1.2M | 8/28/2023 | View on chart |
| ATR | ▼ Sell | Open Market | 300 | $39K | 8/28/2023 | View on chart |
| ATR | ▼ Sell | Open Market | 7,940 | $969K | 8/10/2023 | View on chart |
| PLD | ▼ Sell | Open Market | 10,711 | $1.3M | 8/1/2023 | View on chart |
| PLD | ▼ Sell | Gift | 4,000 | $0 | 7/31/2023 | View on chart |
| ATR | ▲ Buy | Grant | 1,266 | $0 | 5/3/2023 | View on chart |
| ATR | ▼ Sell | Gift | 4,500 | $0 | 9/12/2022 | View on chart |
| ATR | ▲ Buy | Grant | 1,475 | $0 | 5/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Prologis Reports Earnings Beat, Raises 2026 Development Outlook
Prologis posted earnings that exceeded analysts' expectations for the quarter. The company also lifted its 2026 development outlook to $5.75 billion, indicating confidence in future projects. Management noted rent recovery but highlighted ongoing rate‑risk concerns. The stock is trading near a long‑standing support level around $140 and its RSI is below 40, suggesting modest momentum.
Prologis Reports Earnings Beat, Raises 2026 Development Outlook. Prologis posted earnings that exceeded analysts' expectations for the quarter. The company also lifted its 2026 development outlook to $5.75 billion, indicating confidence in future projects. Management noted rent recovery but highlighted ongoing rate‑risk concerns. The stock is trading near a long‑standing support level around $140 and its RSI is below 40, suggesting modest momentum.